Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.

Cyltezo® (adalimumab-adbm) expands treatment options for patients across multiple chronic inflammatory diseases Cyltezo is the only adalimumab biosimilar with Phase III comparative clinical studies in rheumatoid arthritis, plaque psoriasis and Crohn’s disease RIDGEFIELD, Conn., July 1,…